Maxpro Capital Acquisition (JMAC) Competitors

$16.47 +0.25 (+1.51%)

As of 05/4/2026

JMAC vs. PRME, ARVN, ETON, PROK, and ZVRA

Should you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Prime Medicine (PRME), Arvinas (ARVN), Eton Pharmaceuticals (ETON), ProKidney (PROK), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry.

How does Maxpro Capital Acquisition compare to Prime Medicine?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Prime Medicine (NASDAQ:PRME) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

: Maxpro Capital Acquisition has higher earnings, but lower revenue than Prime Medicine.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Maxpro Capital Acquisition N/A N/A N/A N/A N/A
Prime Medicine $4.63M 132.25 -$201.14M -$1.35 N/A
: Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500.
: Maxpro Capital Acquisition has a net margin of 0.00% compared to Prime Medicine's net margin of -4,342.44%. Maxpro Capital Acquisition's return on equity of 0.00% beat Prime Medicine's return on equity.
Company Net Margins Return on Equity Return on Assets
Maxpro Capital Acquisition N/A N/A N/A
Prime Medicine -4,342.44% -178.60% -60.27%
: In the previous week, Prime Medicine had 2 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for Prime Medicine and 0 mentions for Maxpro Capital Acquisition. Prime Medicine's average media sentiment score of 1.22 beat Maxpro Capital Acquisition's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.
Company Overall Sentiment
Maxpro Capital Acquisition Neutral
Prime Medicine Positive
: Prime Medicine has a consensus price target of $7.38, indicating a potential upside of 117.55%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Maxpro Capital Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maxpro Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Prime Medicine
1 Sell rating(s)

3 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.56
: 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 22.7% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Prime Medicine	$4.63M	132.25	-$201.14M	-$1.35	N/A

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Prime Medicine	-4,342.44%	-178.60%	-60.27%

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Prime Medicine	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Prime Medicine	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Prime Medicine beats Maxpro Capital Acquisition on 9 of the 13 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Arvinas?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Arvinas (NASDAQ:ARVN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

: Maxpro Capital Acquisition has higher earnings, but lower revenue than Arvinas.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Maxpro Capital Acquisition N/A N/A N/A N/A N/A
Arvinas $262.60M 2.58 -$80.80M -$1.28 N/A
: Arvinas has a consensus price target of $14.60, indicating a potential upside of 37.61%. Given Arvinas' stronger consensus rating and higher probable upside, analysts clearly believe Arvinas is more favorable than Maxpro Capital Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maxpro Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Arvinas
3 Sell rating(s)

4 Hold rating(s)

9 Buy rating(s)

0 Strong Buy rating(s)
2.38
: In the previous week, Arvinas had 12 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 12 mentions for Arvinas and 0 mentions for Maxpro Capital Acquisition. Arvinas' average media sentiment score of 0.40 beat Maxpro Capital Acquisition's score of 0.00 indicating that Arvinas is being referred to more favorably in the news media.
Company Overall Sentiment
Maxpro Capital Acquisition Neutral
Arvinas Neutral
: Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500.
: Maxpro Capital Acquisition has a net margin of 0.00% compared to Arvinas' net margin of -30.77%. Maxpro Capital Acquisition's return on equity of 0.00% beat Arvinas' return on equity.
Company Net Margins Return on Equity Return on Assets
Maxpro Capital Acquisition N/A N/A N/A
Arvinas -30.77% -14.25% -9.31%
: 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 4.7% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Arvinas	$262.60M	2.58	-$80.80M	-$1.28	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arvinas	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Arvinas	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Arvinas	-30.77%	-14.25%	-9.31%

Summary

Arvinas beats Maxpro Capital Acquisition on 8 of the 12 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Eton Pharmaceuticals?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

: Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
: Maxpro Capital Acquisition has higher earnings, but lower revenue than Eton Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Maxpro Capital Acquisition N/A N/A N/A N/A N/A
Eton Pharmaceuticals $79.95M 10.40 -$4.60M -$0.18 N/A
: 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 16.0% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: In the previous week, Eton Pharmaceuticals had 11 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 11 mentions for Eton Pharmaceuticals and 0 mentions for Maxpro Capital Acquisition. Eton Pharmaceuticals' average media sentiment score of 0.55 beat Maxpro Capital Acquisition's score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
Maxpro Capital Acquisition Neutral
Eton Pharmaceuticals Positive
: Maxpro Capital Acquisition has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -5.75%. Maxpro Capital Acquisition's return on equity of 0.00% beat Eton Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Maxpro Capital Acquisition N/A N/A N/A
Eton Pharmaceuticals -5.75% -2.60% -0.66%
: Eton Pharmaceuticals has a consensus price target of $39.33, suggesting a potential upside of 29.47%. Given Eton Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Maxpro Capital Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maxpro Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Eton Pharmaceuticals
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Eton Pharmaceuticals	$79.95M	10.40	-$4.60M	-$0.18	N/A

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Eton Pharmaceuticals	Positive

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Eton Pharmaceuticals	-5.75%	-2.60%	-0.66%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Eton Pharmaceuticals beats Maxpro Capital Acquisition on 7 of the 12 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to ProKidney?

Maxpro Capital Acquisition (NASDAQ:JMAC) and ProKidney (NASDAQ:PROK) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

: 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Maxpro Capital Acquisition has a net margin of 0.00% compared to ProKidney's net margin of -7,725.20%.
Company Net Margins Return on Equity Return on Assets
Maxpro Capital Acquisition N/A N/A N/A
ProKidney -7,725.20% N/A -18.83%
: ProKidney has a consensus price target of $7.40, indicating a potential upside of 285.42%. Given ProKidney's stronger consensus rating and higher possible upside, analysts clearly believe ProKidney is more favorable than Maxpro Capital Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maxpro Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
ProKidney
2 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.50
: Maxpro Capital Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.
: Maxpro Capital Acquisition has higher earnings, but lower revenue than ProKidney.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Maxpro Capital Acquisition N/A N/A N/A N/A N/A
ProKidney $890K 651.33 -$68.99M -$0.52 N/A
: In the previous week, ProKidney had 2 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for ProKidney and 0 mentions for Maxpro Capital Acquisition. Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled ProKidney'saverage media sentiment score.
Company Overall Sentiment
Maxpro Capital Acquisition Neutral
ProKidney Neutral

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
ProKidney	-7,725.20%	N/A	-18.83%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
ProKidney	$890K	651.33	-$68.99M	-$0.52	N/A

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
ProKidney	Neutral

Summary

ProKidney beats Maxpro Capital Acquisition on 8 of the 11 factors compared between the two stocks.

How does Maxpro Capital Acquisition compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

: Zevra Therapeutics presently has a consensus target price of $23.00, indicating a potential upside of 116.78%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Maxpro Capital Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zevra Therapeutics
0 Sell rating(s)
2 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.78
Maxpro Capital Acquisition
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Zevra Therapeutics has higher revenue and earnings than Maxpro Capital Acquisition.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zevra Therapeutics $106.47M 5.89 $83.23M $1.33 7.98
Maxpro Capital Acquisition N/A N/A N/A N/A N/A
: In the previous week, Zevra Therapeutics had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for Zevra Therapeutics and 0 mentions for Maxpro Capital Acquisition. Zevra Therapeutics' average media sentiment score of 0.00 equaled Maxpro Capital Acquisition'saverage media sentiment score.
Company Overall Sentiment
Zevra Therapeutics Neutral
Maxpro Capital Acquisition Neutral
: Zevra Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500.
: Zevra Therapeutics has a net margin of 78.17% compared to Maxpro Capital Acquisition's net margin of 0.00%. Zevra Therapeutics' return on equity of 57.42% beat Maxpro Capital Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
Zevra Therapeutics 78.17% 57.42% 26.03%
Maxpro Capital Acquisition N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	5.89	$83.23M	$1.33	7.98
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Maxpro Capital Acquisition	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	78.17%	57.42%	26.03%
Maxpro Capital Acquisition	N/A	N/A	N/A

Summary

Zevra Therapeutics beats Maxpro Capital Acquisition on 9 of the 11 factors compared between the two stocks.

Get Maxpro Capital Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JMAC vs. The Competition

Export

Metric	Maxpro Capital Acquisition	Holding Offices Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$221.10M	$231.70M	$4.21B	$11.87B
Dividend Yield	N/A	3.35%	5.61%	5.21%
P/E Ratio	N/A	2.27	23.40	28.47
Price / Sales	N/A	0.14	186.85	60.94
Price / Cash	N/A	123.30	52.82	36.52
Price / Book	N/A	26.66	38.31	6.67
Net Income	N/A	-$8.98M	$114.66M	$332.53M
7 Day Performance	24.83%	0.15%	1.23%	2.01%
1 Month Performance	11.86%	48.07%	5.54%	9.20%
1 Year Performance	164.58%	10.37%	18.68%	39.59%

Maxpro Capital Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JMAC Maxpro Capital Acquisition	N/A	$16.47 +1.5%	N/A	N/A	$221.10M	N/A	N/A	2,021
PRME Prime Medicine	2.1785 of 5 stars	$3.70 -3.6%	$7.38 +99.3%	N/A	$693.32M	$4.63M	N/A	N/A	Positive News Analyst Upgrade
ARVN Arvinas	3.1754 of 5 stars	$10.44 +0.2%	$13.88 +33.0%	N/A	$666.47M	$262.60M	N/A	420	News Coverage Upcoming Earnings Analyst Forecast
ETON Eton Pharmaceuticals	3.9609 of 5 stars	$23.02 +0.2%	$39.33 +70.9%	N/A	$626.72M	$79.95M	N/A	20	News Coverage Upcoming Earnings
PROK ProKidney	1.2159 of 5 stars	$1.94 -3.0%	$7.40 +281.4%	N/A	$603.83M	$890K	N/A	3	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JMAC) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maxpro Capital Acquisition (JMAC) Competitors

JMAC vs. PRME, ARVN, ETON, PROK, and ZVRA

How does Maxpro Capital Acquisition compare to Prime Medicine?

Summary

How does Maxpro Capital Acquisition compare to Arvinas?

Summary

How does Maxpro Capital Acquisition compare to Eton Pharmaceuticals?

Summary

How does Maxpro Capital Acquisition compare to ProKidney?

Summary

How does Maxpro Capital Acquisition compare to Zevra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JMAC vs. The Competition

Maxpro Capital Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maxpro Capital Acquisition (JMAC) Competitors

JMAC vs. PRME, ARVN, ETON, PROK, and ZVRA

How does Maxpro Capital Acquisition compare to Prime Medicine?

Summary

How does Maxpro Capital Acquisition compare to Arvinas?

Summary

How does Maxpro Capital Acquisition compare to Eton Pharmaceuticals?

Summary

How does Maxpro Capital Acquisition compare to ProKidney?

Summary

How does Maxpro Capital Acquisition compare to Zevra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JMAC vs. The Competition

Maxpro Capital Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools